To assess the accuracy of patients' perceptions of the risks associated with localised prostate cancer treatments (radical prostatectomy [RP], radiotherapy [RT], and active surveillance [AS]), and to identify correlates of misperceptions.
Introduction
Prostate cancer is one of the most common cancers diagnosed in men in Europe [1] . Treatment options, also termed management options, for localised prostate cancer include: radical prostatectomy (RP), radiation therapy (RT), and active surveillance (AS) [1] . These options have comparable prostate cancer-specific mortality rates [2] , but differ in the risk of adverse outcomes [3] . For example, although RP and RT have a comparable risk of disease recurrence [2, 4] , RP patients are at more risk of urinary incontinence and erectile dysfunction, and RT patients are more at risk of bowel problems and increased urinary frequency [3, 5, 6] .
Because of the compromises inherent in choosing amongst these various treatment options, prostate cancer guidelines recommend shared decision-making [1, 7, 8] . This is a process of interaction between health professionals and patients in which information is exchanged about treatment options and patients' personal preferences [9, 10] . However, when involving patients in decision making, it is important that they have an accurate understanding of the differences amongst the treatment options [9, 11, 12] . Several qualitative studies have suggested that patients' treatment preferences are frequently based on misperceptions rather than on accurate information [13] [14] [15] [16] . To our knowledge, no quantitative studies have investigated the extent to which patients with prostate cancer have an accurate understanding of the risk of adverse outcomes for the various treatment options [17, 18] . This detailed information about patients' (inaccurate) perceptions, is crucial in the process of creating scalable and durable interventions to improve patients understanding of the differences between prostate cancer treatments [19] .
In the present paper, we report on the results of a quantitative study of: (i) patients' perceptions of the risk of disease recurrence, urinary continence, and erectile dysfunction, and bowel problems associated with RP and RT, and the perceived likelihood of having to eventually undergo definitive treatment after initially opting for AS; (ii) the accuracy of these risk perceptions when compared to the state-of-the-art literature on these topics; and (iii) the factors associated with patients' misperceptions.
Patients and Methods
Between 2014 and 2016, we recruited newly diagnosed patients with clinically localised prostate cancer (cT1-cT2 or Gleason score ≤7, PSA level ≤20 ng/mL) from 13 Dutch clinical facilities (one academic centre, one cancer centre, and 11 community hospitals), as part of a longitudinal observational study of patients with localised prostate cancer. Patients were recruited by the local urologist or clinical nurse specialist after information was provided about the treatment option(s) available to the patient. This included one or more of the following options: RP, external beam radiotherapy (EBRT), brachytherapy (BT), or AS.
For the present analysis, we used data from the baseline questionnaire that was completed after information was provided about the treatment options, but before the start of treatment. Clinical data were obtained from the medical records. Study procedures, including informed consent procedures, were approved by the Medical Ethical Review Committee (reference number WAG/om/14/017805).
Study Measures

Perceived Risks of RP and RT
We assessed patients' risk perceptions (in percentages) regarding the most prevalent adverse events after RP and RT. These included disease recurrence, urinary continence, and erectile dysfunction, and bowel problems. There are different definitions of recurrence after prostate cancer treatments [1] , in our questionnaire we needed to use a definition comprehensible for patients, we therefore defined the risk of recurrence as 'the likelihood of the tumour returning after treatment'. For each risk, response options ranged from a 0% to 100% likelihood of occurrence (Table 1) [1] . We assessed the risks for each treatment option separately (RP, EBRT, and BT); however, patients did not have to answer questions about treatments not offered to them.
Accuracy of the Perceived Differences between RP and RT
Because it is important that patients accurately understand the differences between RP and RT, we defined an 'accurate perception' as a response that was consistent with the direction of the difference between RP and RT reported in the state-of-the-art literature [2] [3] [4] [5] [6] 17, 20, 21] . For example, 'Patient X' rated the likelihood of the tumour returning as 10% for RP and 40% for RT. His answer was categorised as 'RP < RT', and thus as having an 'inaccurate perception' about disease recurrence because there is currently no evidence that RP or RT is associated with an increased risk of primary treatment failure for patients with low-risk prostate cancer [1, 2] . Table 1 describes the details about the adverse events that were rated, and the decision rules for determining the (in)accuracy of the patients' responses [22] .
RT is a collective term for EBRT and BT. We therefore calculated these accuracy scores twice, for RP vs EBRT and for RP vs BT. For both comparisons, the same decision rules for determining the (in)accuracy of responses was applied (Table 1) [5, 23, 24] .
The overall accuracy of perceptions for differences in the risks associated with RP vs EBRT (AccRPvsEBRT), and RP vs BT (AccRPvsBT), was calculated using the following equation:
total # of accurate perceptions total # of perceptions Â 100
Perceived Risks of AS
We formulated two questions about AS (Table 1) : the perceived likelihood of eventually requiring definitive treatment, and the expected effect of AS on mortality compared to definitive treatment [13, 25] .
Accuracy of Perceived Risks of AS
Lacking a widely accepted estimate of the probability of eventually needing definitive treatment after a period of AS, we chose threshold points 10 percentage points beyond the 28% point estimate from a recently published meta-analysis [26] , and the 54% point estimate in the Prostate Testing for Cancer and Treatment (ProtecT) trial [2] , rounding to the nearest tenths place (20-60%; Table 1 ). We defined a patient's rating of the expected effect of AS vs RP or RT on mortality as correct if he agreed that that risk was equivalent [2] . The overall accuracy of patients' perceptions of AS (AccAS) was calculated as described above.
Correlates of Overall Accuracy Scores
We investigated a range of patient and clinical variables as potential correlates of the accuracy of patients' perceptions of risk (Table 2 ). In addition to participants' self-reported sociodemographic and clinical characteristics, we obtained Gleason score, cT-status, and PSA level at time of diagnosis from the medical records. Health-related quality of life (HRQoL) was assessed using the HRQoL scales of the European Organisation for Research and Treatment of Cancer quality-of-life 30-item core questionnaire (EORTC QLQ-C30) and prostate cancer-specific quality-of-life 25-item (QLQ-PR25) questionnaire. All scores are linearly transformed to a 0-100 scale, with higher scores reflecting more symptoms or higher levels of functioning [27, 28] . Psychosocial factors were assessed by study specific questions and the Control Preferences Scale to assess patients' preferred role in treatment decision-making (categorised as active, collaborative, passive) [29] .
Statistical Analysis
We used Student's t-tests and chi-squared tests to compare the characteristics of the men included in and excluded from the analysis.
To avoid over-or underestimation of patients' accuracy rates, we examined the association between risk perception data and: hospital site, prostate cancer risk-group, age, and baseline physical functioning [1] . In case of clustering of the data at the hospital level, we corrected for this by adding hospital as a random effect in the statistical model. In case of a significant association between one or more of the patient characteristics and risk perceptions, we stratified our analyses by subgroup.
We used linear regression to identify univariate predictors of the overall accuracy scales (AccRPvsEBRT, AccRPvsBT, and AccAS). Subsequently, we used multivariate regression analysis, including all variables significant at the univariate level, to identify those factors most strongly associated with the overall accuracy scales.
We performed a sensitivity analysis to examine the stability of the results for AS by replicating these analyses only including low-risk patients. The reason for doing so is that there is considerable variation in selection criteria applied for AS [26, 30] , but current prostate cancer guidelines recommend AS for low-risk patients only [1] .
We considered P ≤ 0.05 as indicative of statistical significance.
Variance explained was used to estimate the strength of 
≤10% ≥70%
Comparable mortality rates for AS, RP, and RT The probability you will die from prostate cancer whilst under AS is as small as the other three treatment options (RP/EBRT/BT). observed associations (i.e., effect size). An R 2 of 0.01 was considered small, 0.09 as moderate, and 0.25 as large [31] .
Results
During the recruitment period, 474 of 546 invited patients (87%) agreed to participate and returned the baseline questionnaire (median timing of response was 2 weeks after diagnosis; interquartile range, 1-4 weeks). For the present analysis, we excluded patients who reported that they had not yet received all information about their prostate cancer treatment options or answered none of the risk perception items (n = 48). There were no significant differences in baseline characteristics (Gleason score, cT-status, PSA level, or age) between those patients included (n = 426) and those excluded from the analysis (n = 120). Characteristics of the patients are presented in Table 2 .
Perceived Risks of RP, RT, and AS Table 3 , on average, patients perceived the following risks of adverse outcomes: disease recurrence -RP 16%, EBRT 30%, and BT 28%; urinary incontinence -RP 39%, EBRT 38%, and BT 34%; erectile dysfunction -RP 50%, EBRT 46%, and BT 39%; bowel problems -RP 23%, EBRT 36%, and BT 31%; and perceived likelihood of eventually requiring definitive treatment after AS, 57% (54% for low-risk patients only). There were no significant associations between the risk perception scales and: hospital site, prostate cancer risk group, age, or baseline physical functioning (P > 0.10; Table S1 ).
As described in
Accuracy of the Perceived Differences between RP and RT
As shown in Figure 1 and Table 4 , only 32% (n = 100) of the patients understood the risk of disease recurrence is similar for RP and EBRT. About one-third (35%, n = 107) of the patients comprehended that RP patients are more at risk of urinary incontinence. Similarly, 39% (n = 120) understood that the risk of erectile dysfunction is higher for RP patients. The accuracy rate did not change considerably (41%, n = 89) when excluding patients with problems with acquiring and retaining an erection (based on QLQ-PR25, item 23). Almost half (47%, n = 142) of the patients understood that the risk of bowel problems is higher after EBRT. Most results were similar (accuracy rate difference <10%) when comparing the risk perceptions of RP with BT (Table 4 ). The only difference concerned erectile dysfunction, 54% of the patients understood this risk is higher after RP compared to BT (vs 39% for RP compared to EBRT).
Accuracy of Perceived Risks of AS
Most patients (45%, n = 157) overestimated the risk of eventually requiring definitive treatment after AS (accuracy rate 43%; Table 4 and Fig. 1 ). Only 20% (n = 82) of the patients understood that mortality rates after AS and definitive treatment are comparable at 10 years [2] . When only including low-risk patients, the accuracy rates increased slightly (eventually requiring definitive treatment, 51%, n = 76; mortality, 24%, n = 40).
Predictors of Overall Accuracy of Perceived Risk
Univariate correlates of overall accuracy scores (AccRPvsEBRT, AccRPvsBT, and AccAS) are presented in Table 2 . At the multivariate level, delivery of treatment information by a radiotherapist was a significant predictor of a better understanding of differences between RP and EBRT (the average accuracy rate for those who spoke to a radiotherapist was 50%, vs 37% for those who did not; full model R 2 = 0.038). Similarly, delivery of treatment information by a clinical nurse specialist was a multivariate predictor of better understanding of differences between RP and BT (the average accuracy rate for those who spoke to a clinical nurse specialist was 45%, vs 40% for those who did not; full model R 2 = 0.016). No patient or tumour characteristics were associated significantly with AccRPvsEBRT or AccRPvsBT.
Significant univariate correlates of better understanding of AS were: Gleason-score 6 (R 2 = 0.046), receiving information from a urologist (R 2 = 0.018), and lower levels of emotional distress (R 2 = 0.013). Only Gleason score remained statistically significant in the full model (R 2 = 0.063), and when excluding high-and intermediate-risk group patients, none of the variables remained significantly associated with the overall AS accuracy score.
Discussion
To our knowledge, the present study is the first to investigate patients' perceptions of the risks of adverse outcomes after prostate cancer treatment prior to their receiving treatment. Consistent with previous qualitative studies, our present results indicate that most patients' risk perceptions' deviate from risk outcomes reported in the literature [13] [14] [15] [16] .
Many patients had inaccurate understanding of the differences between RP and RT in clinical outcomes and the risk of adverse events. More than half of the patients inaccurately perceived RP as being more effective than RT for risk of disease recurrence, and most patients underestimated the risks of side-effects after RP compared to RT (urinary incontinence, erectile problems, and bowel problems). These patients are at risk of making less than fully informed treatment decisions and of experiencing unexpected or disappointing outcomes [10, 11] .
Our present results indicate that patients who received information from a clinical nurse specialist or a radiotherapist were more likely to have accurate perceptions of differences between RP and RT. These findings emphasise the importance of discussing treatment options in a multidisciplinary team [1] . However, the variables included in our present analysis only explained a small proportion (2-9%) of the variance in misperceptions. Additional research is needed to identify a broader range of factors (e.g. patient-, health professional-, communication-, and hospital-level factors) that contribute to these misperceptions, and how they can be corrected prior to patients' choosing amongst the various treatment options [17, 19, 32, 33] . As a next step we would recommend an observational study in which conversations of patients with different types of health professionals are recorded and content analysed. This information should yield more insight into the causes of the misperceptions (e.g., inadequate information provision, patients' selective memory, or a combination of both).
The patients' perceptions of adverse outcomes after AS also differed significantly from risk estimates reported in the literature. Most patients overestimated the likelihood of eventually needing to start definitive treatment after a period of AS, and overestimated the mortality rates for AS as compared to definitive treatments. This might explain the fact that most patients who are eligible for AS prefer other treatments [34] . Inaccurate perceptions about AS were particularly prevalent among patients with high levels of distress, similar to the finding of Orom et al. [18] that emotional distress increased the likelihood of undergoing surgery amongst patients with prostate cancer. In addition, these results support the conclusion of Denberg et al. [13] that the treatment decisionmaking process would benefit from interventions, and particularly shared decision-making programmes, that moderate feelings of fear and dispel common misperceptions about prostate cancer and its treatment options.
The findings presented here should be considered in the context of the study's limitations. Due to the paucity of validated measures, our questions assessing risk perceptions and their accuracy were specifically developed for the present study. The availability of validated measures for assessing the accuracy of patients' treatment perceptions would facilitate cross-study comparisons, and help to optimise the shared decision-making process [19] . Additionally, it is possible that patients received and/or sought additional information from health professionals or from other sources after they had completed their baseline questionnaire. Consequently, the accuracy of their perceptions might have changed before their actually making a treatment decision. However, in our present sample, the patients who already had decided about their treatment before completing the questionnaire did not have significantly better accuracy rates than those who had not (Table 2) .
A last important issue concerns the use of the term 'accurate perceptions'. Our decision rules for 'accurate perceptions' are based on a review of recently published clinical series [1, 3] . Thus, in the present context, the term 'accurate perception' actually means that the patients' risk perception corresponded to current scientific insights. However, there still remains controversy about risk estimates and differences among prostate cancer treatment options described in published series. This controversy is mostly related to concerns about clinics, patients, excellence of physicians, and techniques that do not represent real-world practice. These concerns are reflected in differences between physicians in their beliefs and thus in the information that they share with patients about risk estimates and differences among treatments. Therefore, it might be that some patients received information (legitimately or not) deviating from current scientific insights. Further improvement of well-informed shared decisionmaking requires agreement about differences among the prostate cancer treatment options, and at the patients' level, improved knowledge about the risks of adverse events per treatment option [17] . Our present study also has several strengths, including a large sample size, inclusion of patients primarily from community hospitals rather than specialised cancer centres (as is typical of many studies), a high response rate, and the use of a prospective design. Another strength of the present study is the method used to assess the patients' risk perceptions and misperceptions (quantitatively assessing perceived risks per treatment option). Therefore, the clinical utility of the present study is elevated compared to previous studies that, mostly qualitatively, assessed less specific constructs like 'prostate cancer knowledge' (containing a variety of prostate cancerrelated concepts) [13] [14] [15] [16] 35] . The detailed information about what exact risks are often misperceived by patients, and factors contributing to more accurate perceptions, provide concrete and practical information for developers of interventions (e.g. decision tools) aimed to improve patients understanding of the differences between prostate cancer treatments [19] .
Conclusion
The results of this multi-centre study emphasise the need for health professionals involved in the treatment and care of patients with prostate cancer to be aware that many of their patients may have inaccurate ideas about the risks associated with the various treatment options, and thus may make choices that are less than well-informed, which may lead to unexpected or disappointing outcomes. Efforts are needed to better understand why these misperceptions occur, their impact on outcomes and, most importantly, how they can be corrected before patients' choosing a treatment. radiotherapy; EORTC, European Organisation for Research and Treatment of Cancer; HRQoL, health-related quality of life; QLQ-C30, quality-of-life 30-item core (questionnaire); QLQ-PR25, prostate cancer-specific quality-of-life 25-item (questionnaire); RP, radical prostatectomy; RT, radiation therapy.
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